Hybridoma-based Anti-idiotypic mAb Discovery against a Bispecific Therapeutics for PK/ADA Assays Development

Products

Applications

resources

COMPANY

Hybridoma-based Anti-idiotypic mAb Discovery against a Bispecific Therapeutics for PK/ADA Assays Development

View the Case Study

Download the Case Study

Case study showcasing a campaign for the discovery of panels of anti-idiotypic mAb’s for a bispecific molecule to be used for PK/ADA Assay Development.

Covered in this Case Study

Anti-idiotypic, bispecific discovery case study

Rapid immunization of 2 cohorts of mice. Screening by Elisa and Octet

Delivered: oHC/LC sequences and purified and validated mAb one week ahead of schedule

Genes

Oligo Pools

NGS Target Enrichment Solutions

Variant Libraries

Hybridoma-based Anti-idiotypic mAb Discovery against a Bispecific Therapeutics for PK/ADA Assays Development

Related Resources

Twist cfDNA Pan-Cancer Reference standard VAF 0% (WT), 3ug (SDS-001098)

ANTI-IDIOTYPIC MAB DISCOVERY PART I: SCREENING STRATEGY FOR ANTI-IDIOTYPIC MAB (ANTI-ID) AS CRITICAL PK/ADA AS

Synthetic DNA: The Fabric of Modern Cancer Research

Share your details to Get the Case Study